BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea

This is a cleaner outcome for BMRN than for ASND. The economic read-through is not the headline royalty rate itself, but the fact that BioMarin has effectively converted IP friction into a toll-booth on a competing CNP asset while preserving the exclusivity halo around its own franchise. That matters because rare-disease investors pay up for durable cash flow visibility; a validated IP perimeter can support multiple expansion for BMRN if the market starts to believe the franchise is harder to displace than previously modeled.

For ASND, the overhang is removed, but the price is a permanent tax on operating leverage in a product that likely needs high gross-to-net efficiency to justify launch economics. The near-term reaction can still be positive because injunction risk is gone, yet over 6-18 months the settlement cap on margins may force a lower terminal profit pool than bulls were underwriting. Second-order, this also raises the bar for any would-be CNP competitors: rather than a clean race to market, the category now looks more like a licensed duopoly with BioMarin capturing economics even where it is not the commercial seller.

The key risk is that investors overestimate the cash impact before there is visible sell-through. If Yuviwel sales ramp slowly, BMRN’s royalty stream is immaterial and the settlement becomes mostly symbolic; if launch momentum is strong, the stream could become a meaningful incremental annuity. Contrarian view: ASND may be the better short only after an initial relief rally, because the market could ignore that a 20% U.S. royalty is materially dilutive to peak operating margin assumptions.